Phase III Randomized Study of Adjuvant Ipilimumab Versus High-Dose Recombinant Interferon Alfa-2b in Patients With High-Risk Stage IIIB, IIIC, or IV Melanoma (Ipilimumab Provided)
ECOG E1609   (MBMC Contact: Chris Joyce 314-996-5536)  Click For Consent ***

Phase II Randomized Study of Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Patients With Metastatic Malignant Melanoma (Everolimus and Bevacizumab Provided)
NCCTG N0879   (MBMC Contact: Chris Joyce 314-996-5536)  Click For Consent  (TEMPORARILY CLOSED TO ENROLLMENT)

***Available through CTSU